However, a recently updated meta-analysis indicated that anti-EGFR therapies could remain an option for patients with RAS wildtype right-sided tumours, as this significantly improved PFS and therapy response in both left- and right-sided tumours [9]. This evidence concerns the gene EGFR and neoplasm.